You just read:

Health Canada grants market authorization to ROZLYTREK® (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib(1)

News provided by

Hoffmann-La Roche Limited (Roche Canada)

May 20, 2020, 10:49 ET